Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:
- an article about the recent Federal Circuit decision that “vacated a $576 million judgment against Apple”; and
- a blog post about the Solicitor General’s recent “amicus brief with the United States Supreme Court advising it to grant Teva Pharmaceuticals’ petition for writ of certiorari.”
Ryan Davis wrote an article for Law360 about the recent Federal Circuit decision that “vacated a $576 million judgment against Apple” related to “two VirnetX network security patents.” Davis explained how the vacated judgment came after the Federal Circuit upheld the “Patent Trial and Appeal Board decisions that . . . two VirnetX network security patents are invalid.” Davis reported how VirnetX “has been battling with Apple over patents since 2010, and the case has included multiple retrials and appeals.”
Eileen McDermott authored a blog post for IPWatchdog about “[t]he U.S. Solicitor General . . . fil[ing] an amicus brief with the United States Supreme Court advising it to grant Teva Pharmaceuticals’ petition for writ of certiorari.” McDermott highlighted how the petition “relat[es] to generic manufacturers’ liability for infringement through the use of ‘skinny labels’ on generic drugs.” McDermott reported how the amicus brief said that the Federal Circuit “got it wrong, and that the decision could upend the careful balance contemplated by the Hatch-Waxman Amendments between incentivizing new brand name drugs and allowing cheaper generics into the market.”